{Reference Type}: Journal Article
{Title}: Progress in managing children with achondroplasia.
{Author}: Taylor-Miller T;Savarirayan R;
{Journal}: Expert Rev Endocrinol Metab
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 12
暂无{DOI}: 10.1080/17446651.2024.2390416
{Abstract}: <B>UNASSIGNED: </B>Achondroplasia is a heritable disorder of the skeleton that affects approximately 300,000 individuals worldwide. Until recently, treatment for this condition has been purely symptomatic. Efficacious treatment options for children are now approved or are in clinical trials.<BR><B>UNASSIGNED: </B>This review discusses key advances in the therapeutic management of children with achondroplasia, including vosoritide, the first approved drug, and other emerging precision therapies. These include navepegritide, a long-acting form of C-type natriuretic peptide, and infigratinib, a tyrosine kinase receptor inhibitor, summarizing trial outcomes to date.<BR><B>UNASSIGNED: </B>The advent of the first approved precision therapy for achondroplasia in vosoritide has been a paradigm shifting advance for children affected by this condition. In addition to changing their natural growth history, it is hoped that it will decrease their medical complications and enhance functionality. These new treatment options highlight the importance of prompt prenatal identification and subsequent testing of a suspected fetus with achondroplasia and counseling of families. It is hoped that, in the near future, families will have the option to consider a range of effective targeted therapies that best suit their child with achondroplasia, starting from birth should they choose.